MILIND JAVLE to Quinazolines
This is a "connection" page, showing publications MILIND JAVLE has written about Quinazolines.
Connection Strength
0.451
-
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep. 2021 07 16; 23(9):108.
Score: 0.140
-
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368.
Score: 0.065
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
Score: 0.063
-
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol. 2008 Aug; 31(4):329-34.
Score: 0.057
-
Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology. 2007; 73(5-6):281-9.
Score: 0.056
-
Gemcitabine and acute myocardial infarction--a case report. Angiology. 2006 May-Jun; 57(3):367-71.
Score: 0.049
-
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
Score: 0.020